Durgical
EN
Open the app

Juvenile dermatomyositis

  • Topic

Juvenile dermatomyositis is a rare autoimmune disease that inflames the skin, the muscles and the small blood vessels. Many need long treatment.

Updated

What it is

Juvenile dermatomyositis (JDM) is the most common idiopathic inflammatory myopathy of childhood, though still rare (about 3 per million children a year in the USA). It affects skin, muscle and blood vessels, with systemic features in some children. Its cause is not fully understood; immune dysregulation (especially of B cells), mitochondrial dysfunction, neutrophil changes and increased interferon signalling are described. Myositis-specific autoantibodies define clinical subgroups: anti-TIF1 (the commonest) with photosensitivity, skin ulceration and chronic or polycyclic disease; anti-NXP2 with myalgia, dysphonia, dysphagia, calcinosis, more severe weakness and less remission; and anti-MDA5 (more common in Japan) with less weakness but interstitial lung disease and systemic features such as fever and weight loss. Most children do not fully respond to initial therapy and follow a chronic, refractory or polycyclic course.

Key facts

  • Most common inflammatory myopathy of childhood, but rare.
  • Involves skin, muscle and vessels; some children have lung, gut or heart involvement.
  • Autoantibody subgroups predict features: anti-TIF1 (skin ulcers, chronic course), anti-NXP2 (calcinosis, dysphagia, severe weakness), anti-MDA5 (interstitial lung disease).
  • First-line treatment is usually corticosteroids with methotrexate; refractory disease needs other options, including biologics (no doses here).
  • Most children have a chronic or relapsing course rather than a single episode.

Step by step

  1. Suspect JDM in a child with muscle weakness and a skin rash.
  2. Measure muscle enzymes such as creatine kinase and test myositis-specific autoantibodies.
  3. Screen for lung, swallowing, gut and heart involvement according to the subgroup.
  4. Start treatment with paediatric rheumatology per guideline.
  5. Monitor disease activity, growth and complications such as calcinosis.
  6. Plan long-term follow-up for a chronic or relapsing course.

Myositis-specific autoantibodies in JDM

AutoantibodyFrequencyAssociated features
Anti-TIF1Most commonPhotosensitivity, skin ulceration, chronic or polycyclic course
Anti-NXP2Next most commonMyalgia, dysphonia, dysphagia, calcinosis, more severe weakness, less remission
Anti-MDA5More common in JapanLess weakness; interstitial lung disease, fever, weight loss

In clinical practice

  • Swallowing and voice problems signal more severe disease and aspiration risk.
  • Calcinosis can appear during the course and affects function.

Next step / Initial management

  • Muscle enzymes (creatine kinase), myositis-specific autoantibodies, and imaging or tests for lung, gut and heart involvement by subgroup.
  • Monitoring of disease activity and treatment side effects.
  • Suspected JDM: refer to paediatric rheumatology; dysphagia, breathing problems or lung disease: urgent referral.

Common traps

  • JDM is the adult disease in a child: it is a distinct childhood disease with its own autoantibody subgroups.
  • A child with weakness and a normal-looking skin cannot have JDM: some subgroups have little weakness or mostly skin and lung disease.
  • One course of treatment cures most children: most have a chronic, refractory or relapsing course.
  • The autoantibody result does not change care: it predicts lung disease, calcinosis and the course.

Test yourself

Think of the answer, then tap the question to see it.

Which autoantibody in JDM is linked with interstitial lung disease?

Anti-MDA5.

Which subgroup is associated with calcinosis and dysphagia?

Anti-NXP2.

What course do most children with JDM follow?

A chronic, refractory or polycyclic course rather than full response to initial therapy.

Add to my cards (3)

Connections

← All of pediatrics

Educational content; it does not replace assessment by a doctor and is not a clinical instruction. If a child has difficulty breathing, cannot drink, vomits everything, has a seizure, is very drowsy, or is a baby under three months with fever, go to an emergency department at once.

Sources: Juvenile Dermatomyositis: Updates in Pathogenesis and Biomarkers, Current Treatment, and Emerging Targeted Therapies (Paediatric Drugs (open access, Europe PMC), 2025).

Spotted a mistake?We are always improving for the community. Tell us what is wrong and our team will review it.Report a mistake

Representative model, for educational purposes only.